Q-Line Biotech Stock Price Analysis and Quick Research Report. Is Q-Line Biotech an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Q-Line Biotech. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Q-Line Biotech has a PE ratio of 28.600688186138 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Q-Line Biotech has ROA of 11.4546% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Q-Line Biotech has a Current ratio of 1.6593.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Q-Line Biotech has a ROE of 26.0452%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Q-Line Biotech has a Debt to Equity ratio of 0.8608 which means that the company has low proportion of debt in its capital.

• Sales growth: Q-Line Biotech has reported revenue growth of 8.9704% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Q-Line Biotech for the current financial year is 29.0680516733576%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Q-Line Biotech is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Q-Line Biotech is Rs 24.412. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Q-Line Biotech in Ticker for free. Also, one can get the intrinsic value of Q-Line Biotech by using Valuation Calculators, which are available with a Finology ONE subscription. 

Q-Line Biotech FAQs

Q1. What is Q-Line Biotech share price today?
Ans: The current share price of Q-Line Biotech is Rs 698.2.

Q2. What is the market capitalisation of Q-Line Biotech?
Ans: Q-Line Biotech has a market capitalisation of Rs 1628.77485418 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Q-Line Biotech?
Ans: The PE ratio of Q-Line Biotech is 28.600688186138 and the P/B ratio of Q-Line Biotech is 3.32868023692652, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Q-Line Biotech share?
Ans: The 52-week high share price of Q-Line Biotech is Rs 730, and the 52-week low share price of Q-Line Biotech is Rs 431.

Q5. Does Q-Line Biotech pay dividends?
Ans: Currently, Q-Line Biotech does not pay dividends. Dividend yield of Q-Line Biotech is around 0%.

Q6. What are the face value and book value of Q-Line Biotech shares?
Ans: The face value of Q-Line Biotech shares is Rs 10, while the book value per share of Q-Line Biotech is around Rs 209.7528. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Q-Line Biotech?
Ans: Q-Line Biotech has a total debt of Rs 212.9617 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Q-Line Biotech?
Ans: The ROE of Q-Line Biotech is 26.0452% and ROCE of Q-Line Biotech is 23.0025%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Q-Line Biotech a good buy for the long term?
Ans: The Q-Line Biotech long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Q-Line Biotech undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Q-Line Biotech appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Q-Line Biotech’s financials?
Ans: You can review Q-Line Biotech’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.